Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

Journal of Infectious Diseases

Volumn 174, Issue 4, 1996, Pages 713-721

  Luzuriaga, Katherine ^a   Bryson, Yvonne ^b   McSherry, George ^b   Robinson, James ^b   Stechenberg, Barbara ^b   Scott, Gwendolyn ^b   Lamson, Michael ^b   Cort, Susannah ^b   Sullivan, John L ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RESISTANCE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

EID: 0029845343     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.4.713     Document Type: Article

References (15)

1. Newell ML, Peckham C, Dunn D, Ades T, Giaquinto C. Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study. Pediatrics 1994;94:815-9.
2. Merluzzi VJ, Hargrave K, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250: 1411-3.
3. Richman D, Rosenthal A, Skoog M, Eckner R, Sabo J, Merluzzi V. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergizes with zidovudine. Antimicrob Agents Chemother 1991;35:305-8.
4. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37:178-82.
5. Richman DD, Shih CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88: 11241-5.
6. Cheeseman S, Murphy R, Saag M, Havlir D. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in [abstract]. In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993.
7. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;(suppl 21):77.
8. Havlir D, Cheeseman S, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
9. AIDS Clinical Trials Group. Virology reference manual. Bethesda, MD: National Institutes of Health, 1993.
10. Japour AJ, Mayers DL, Johnson VA, et al. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
11. Richman D, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
12. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
13. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
14. Dueweke T, Pushkarskaya T, Poppe S, et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci USA 1993;90:4713-7.
15. Larder B. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;36:2664-9.